ホーム>>Peptides>>Atrial Natriuretic Peptide (ANP) (1-28), rat TFA

Atrial Natriuretic Peptide (ANP) (1-28), rat TFA (Synonyms: Atrial natriuretic factor (1-28) (rat) TFA)

カタログ番号GC35426

心房性ナトリウム利尿ペプチド (ANP) (1-28)、ラット (TFA) は、ラットにおける ANP の主要な循環型であり、アンジオテンシン II (Ang II) 刺激によるエンドセリン-1 分泌を濃度依存的に強力に阻害します。

Products are for research use only. Not for human use. We do not sell to patients.

Atrial Natriuretic Peptide (ANP) (1-28), rat TFA 化学構造

サイズ 価格 在庫数 個数
500μg
$167.00
在庫あり
1mg
$260.00
在庫あり
5mg
$908.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Atrial Natriuretic Peptide (ANP) (1-28), rat (TFA) is a major circulating form of ANP in rats, potently inhibits Angiotensin II (Ang II)-stimulated endothelin-1 secretion in a concentration-dependent manner. Endothelin-1[1]

Rat ANP (1-28) and rat BNP-45, which are the respective major circulating forms of ANP and BNP in rats, potently inhibited Ang II-stimulated endothelin-1 secretion in a concentration-dependent manner. Rat ANP (5-25) is less effective that Rat ANP(1-28) with respect to inhibiting immunoreactive (ir)-endothelin-1 secretion and increasing cellular cyclic GMP. Rat ANP (1-28) inhibits the secretion of ir-endothelin-1 in a concentration-dependent manner between 0.01 and 1 μM[1].

[1]. Kohno M, et al. Angiotensin II stimulates endothelin-1 secretion in cultured rat mesangial cells. Kidney Int. 1992 Oct;42(4):860-6.

レビュー

Review for Atrial Natriuretic Peptide (ANP) (1-28), rat TFA

Average Rating: 5 ★★★★★ (Based on Reviews and 1 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Atrial Natriuretic Peptide (ANP) (1-28), rat TFA

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.